Filing Flows › Cue Biopharma (CUE) › Q4 2024
Cue Biopharma (CUE) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Cue Biopharma (CUE) reported revenue of $1.6M for the fourth quarter 2024 (Q4 2024), -13% from a year earlier and -53% from the quarter before. Operating margin was -611.2%, net loss $9.5M (602.5% of revenue).
Cue Biopharma, Q4 2024: revenue $1.6M (-14% year over year), operating margin -611.2%, net loss $9.5M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -53% | -13% |
| Operating profit | −$9.6M | — | — |
| Net earnings | −$9.5M | — | — |
| Operating cash flow | −$9.0M | — | — |
What changed
Revenue was $1.6M in Q4 2024, down 13% year over year and down 53% from the previous quarter.
Operating costs exceeded revenue by $9.6M, an operating margin of -611.2%. Total costs fell 28% while revenue fell 13%. The quarter ended with a net loss of $9.5M, wider than the previous quarter's $8.7M loss.
Operating cash flow was −$9.0M. Non-cash charges added back $98K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $1.2M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$9.0M.
Questions
What was Cue Biopharma's revenue in the fourth quarter 2024?
Cue Biopharma (CUE) reported revenue of $1.6M for the fourth quarter 2024 (Q4 2024), -13% from a year earlier and -53% from the quarter before.
Was Cue Biopharma profitable in the fourth quarter 2024?
Operating loss was $9.6M (-611.2% of revenue) and net loss $9.5M.
Source: Cue Biopharma 10-K on SEC EDGAR.